Date: October 28, 2022  Administrative Circular: 2022:43

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

Content has been added for the Pfizer primary series of 4 doses (3 mcg) for those 6 months to 4 years of age who are moderately to severely immunosuppressed. Moderna remains the preferred product for this population.

Please remove page numbers: 1-3 dated October 11, 2022
Please add new page numbers: 1-3 dated October 28, 2022

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) 5-11 years of age (Orange Vial Cap)

Footnote B on page 1 has been amended to remove, “if the second dose is given as the 10 mcg formulation, this dose should be considered valid and the series complete.” When a client transitions to a different age within the primary series or booster dose, the client should be immunized with the age-appropriate product based on age at presentation. NOTE: Any 10 mcg doses that were previously validated prior to October 28, 2022 can remain valid in the Provincial Immunization Registry.

Please remove page numbers: 1-5 dated September 23, 2022
Please add new page numbers: 1-5 dated October 28, 2022
COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) 6 months to 4 years of age (Maroon Vial Cap)

- Under Doses and Schedule, content has been added for individuals who are moderately to severely immunosuppressed that if Moderna is unavailable, or upon client request, Pfizer-BioNTech can be given as a 4-dose primary series with the 4th dose provided 28 days after the 3rd dose.
- Under Special Considerations, a footnote has been added to include references on co-administration.

Please remove page numbers: 1-5 dated September 23, 2022
Please add new page numbers: 1-5 dated October 28, 2022

The Guidance on the Management of Inadvertent COVID-19 Vaccine Errors has been updated and will be posted shortly.
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease,
Population and Public Health Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division